ArticleJournal of cachexia, sarcopenia and muscle2025
Temporal Muscle Thickness as a New Biomarker: Its Association With Alzheimer Pathology and Cognitive Impairment in Chinese Adults.
Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Advancing Alzheimer's disease research in China: insights, innovations, and future directions from the chinese preclinical Alzheimer's disease study (CPAS).Molecular psychiatry · 2026Review
- Sarcopenia in cognitive disorders: Toward a shared pathophysiological framework.Osteoporosis and sarcopenia · 2026Review
- Integrated Analysis of Cerebral Small Vessel Disease and Facial Soft-Tissue Markers in the Alzheimer's Disease Continuum.Brain sciences · 2026Article
- Association between temporal muscle morphology based on MRI and muscle mass and strength in healthy young adults: a cross-sectional study.BMC musculoskeletal disorders · 2026Article
- Temporal Muscle Thickness as a New Biomarker: Its Association With Alzheimer Pathology and Cognitive Impairment in Chinese Adults.Journal of cachexia, sarcopenia and muscle · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe association between skeletal muscle mass loss and cognitive decline remains unclear. Temporal muscle thickness (TMT) has been validated as an easily obtainable surrogate marker for muscle mass loss in neurological patients. This study was aimed at exploring whether a decline in TMT correlates with Alzheimer's disease (AD)-related cognitive impairment and its underlying mechanisms.
methodsThis study was a cross-sectional substudy of the Chinese preclinical AD study, which included data from 801 participants. TMT was measured using cranial magnetic resonance imaging. Appendicular skeletal muscle index (ASMI) was estimated using an anthropometric equation as a control. Cognitive function was assessed using a battery of standardised neuropsychological tests, and participants were categorised into three groups based on clinical diagnosis: normal cognition (NC), mild cognitive impairment (MCI) and AD. Functional performance was evaluated using the Functional Activities Questionnaire. Of the 801 participants, 733 underwent
resultsSignificant differences in TMT measurements were observed by age and sex, with thinner TMT found in females and older adults. TMT was significantly associated with ASMI, handgrip strength and mobility. Regarding cognition, TMT, but not ASMI, was thinner in MCI and AD participants than those with NC. TMT was positively correlated with Montreal Cognitive Assessment-Basic (MoCA-B) scores (r = 0.124, p = 0.001), independent of confounders such as age, sex, education level, nutritional risk, history of hypertension and apolipoprotein E ε4 genotype. Among cognitive domains, TMT was most closely associated with performance on the Auditory Verbal Learning Test recognition (p < 0.05). Stratified analyses revealed that the correlation between TMT and MoCA-B remained significant in MCI participants but not in AD participants. Multivariable logistic regression analysis showed that higher TMT was significantly associated with a lower risk of MCI (OR: 0.494, 95% CI: 0.287-0.849, p < 0.05) and a reduced likelihood of functional dependence (OR: 0.791, 95% CI: 0.670-0.935, p < 0.01). Furthermore, TMT was lower in participants with higher brain tau deposition and was negatively associated with tau PET Braak stages (both p < 0.01).
conclusionsA decline in TMT was associated with worse cognitive function, increased cerebral tau deposition and impaired functional performance. TMT may serve as a simple, noninvasive and cost-effective marker for MCI due to AD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.